ORIC
ORIC Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+13/100
Last price
12.05
▼ 0.44 (3.52%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
12.48
Prev close
12.49
Day high
12.60
Day low
11.56
Volume
2.09M
Market cap
$1.24B
P/E (TTM)
—
52W range
7.23 – 14.93
Day trading desk
Gap from prior close
-0.08%
Prior close 12.49
VWAP
11.92
+1.10% from price
Relative volume
2.68×
Unusually busy
Session range
9.00%
11.56 – 12.60
Position in range
47%
Mid range
ATR (14D)
0.79
6.53% of price
Prior day high
12.65
PDH
Prior day low
11.89
PDL
Bid / ask spread
—
Quote not published
Session volume
3.96M
Avg 1.48M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-10.40%
-12.3%
1M
-6.84%
-8.0%
3M
+9.91%
+5.4%
6M
+35.06%
+16.9%
YTD
+46.45%
+32.2%
1Y
+3.59%
-12.8%
3Y
+98.02%
+15.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ORIC open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-9.90K
Net selling
Buy transactions
3
93.90K shares
Sell transactions
4
103.80K shares
Net transactions
+7
Buys less sells
Sell : buy shares
1.1 : 1
Mixed
Insider-held shares
1.64M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 28, 26 | PISCITELLI DOMINIC G. Chief Financial Officer |
SELL | 13.40K | $181.26K | Direct |
| Sep 28, 26 | PISCITELLI DOMINIC G. Chief Financial Officer |
CONVERSION | 13.40K | $58.42K | Direct |
| Aug 26, 26 | PISCITELLI DOMINIC G. Chief Financial Officer |
SELL | 77.00K | $1.05M | Direct |
| Aug 26, 26 | PISCITELLI DOMINIC G. Chief Financial Officer |
CONVERSION | 77.00K | $376.72K | Direct |
| Jul 24, 26 | HEYMAN RICHARD A Director |
SELL | 13.10K | $157.46K | |
| Jul 24, 26 | HEYMAN RICHARD A Director |
CONVERSION | 3.50K | $5.60K | Direct |
| Jul 6, 26 | HEYMAN RICHARD A Director |
SELL | 300 | $3.60K | Indirect |
| Feb 24, 26 | PISCITELLI DOMINIC G. Chief Financial Officer |
SELL | 52.00K | $702.69K | Direct |
| Feb 24, 26 | PISCITELLI DOMINIC G. Chief Financial Officer |
CONVERSION | 52.00K | $226.72K | Direct |
| Jan 16, 26 | HEYMAN RICHARD A Director |
SELL | 6.70K | $80.43K | |
| Dec 16, 25 | MULTANI PRATIK S Officer |
SELL | 10.72K | $97.13K | Direct |
| Dec 16, 25 | CHACKO JACOB M Chief Executive Officer |
SELL | 33.37K | $302.37K | Direct |
| Dec 16, 25 | PISCITELLI DOMINIC G. Chief Financial Officer |
SELL | 10.72K | $97.13K | Direct |
| Dec 15, 25 | MULTANI PRATIK S Officer |
— | 29.33K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHACKO JACOB M |
Chief Executive Officer | 581.71K | Sale |
HEYMAN RICHARD A |
Director | — | Sale |
KUNKEL LORI ANNE |
Director | 84.20K | Conversion of Exercise of derivative security |
MULTANI PRATIK S |
Officer | 68.15K | Sale |
PISCITELLI DOMINIC G. |
Chief Financial Officer | 69.83K | Sale |
YOU ANGIE J. PH.D. |
Director | 28.00K | Purchase |
Fundamentals
Market cap$1.24B
Enterprise value$983.00M
Revenue (TTM)—
Gross profit—
EBITDA$-155.00M
Net income$-140.35M
EPS (TTM)$-1.27
Free cash flow$-68.83M
Total cash$264.76M
Total debt$6.00M
Book value / share$3.68
Shares outstanding103.65M
Float88.69M
Short % of float17.09%
Dividend yield0.00%
Beta (5Y)0.98
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.16
PEG ratio—
Price / sales—
Price / book3.26
EV / revenue—
EV / EBITDA-6.34
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-39.80%
Return on assets-25.97%
Debt / equity1.57
Current ratio13.19
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $109.82M | $114.07M | $85.17M | $61.68M | — | -3.7% |
| Selling, general & admin | $33.19M | $28.82M | $25.61M | $25.09M | — | +15.1% |
| Total operating expense | $143.00M | $142.90M | $110.78M | $86.77M | — | +0.1% |
| Operating income | -$143.00M | -$142.90M | -$110.78M | -$86.77M | — | -0.1% |
| Net interest income | — | — | — | $2.65M | $141.00K | — |
| Pre-tax income | -$129.47M | -$127.85M | -$100.70M | -$89.12M | — | -1.3% |
| Net income | -$129.47M | -$127.85M | -$100.70M | -$89.12M | — | -1.3% |
| Net income to common | -$129.47M | -$127.85M | -$100.70M | -$89.12M | — | -1.3% |
| Basic EPS | -1.47 | -1.83 | -1.96 | -2.25 | — | +19.7% |
| Diluted EPS | -1.47 | -1.83 | -1.96 | -2.25 | — | +19.7% |
| EBIT | -$143.00M | -$142.90M | -$110.78M | -$86.77M | — | -0.1% |
| EBITDA | -$141.78M | -$141.79M | -$109.75M | -$85.80M | — | +0.0% |
| Basic shares | 87.79M | 69.73M | 51.45M | 39.66M | — | +25.9% |
| Diluted shares | 87.79M | 69.73M | 51.45M | 39.66M | — | +25.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $45.67M | $59.41M | $23.38M | $66.84M | -23.1% |
| Cash & short-term investments | $281.49M | $255.96M | $208.19M | $206.27M | +10.0% |
| Total current assets | $288.47M | $262.25M | $212.60M | $210.46M | +10.0% |
| Property, plant & equipment | $2.42M | $2.92M | $2.86M | $3.25M | -17.4% |
| Total assets | $408.89M | $274.14M | $252.01M | $247.18M | +49.2% |
| Total current liabilities | $20.42M | $24.85M | $20.46M | $15.39M | -17.8% |
| Total debt | $3.33M | $3.18M | $2.75M | $2.66M | +4.6% |
| Total liabilities | $24.53M | $31.02M | $27.92M | $24.83M | -20.9% |
| Retained earnings | -$692.24M | -$562.77M | -$434.93M | -$334.23M | -23.0% |
| Shareholder equity | $384.36M | $243.12M | $224.09M | $222.35M | +58.1% |
| Working capital | $268.05M | $237.40M | $192.14M | $195.07M | +12.9% |
| Net tangible assets | $384.36M | $243.12M | $224.09M | $222.35M | +58.1% |
| Shares issued | 98.53M | 71.02M | 54.87M | 45.09M | +38.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$129.47M | -$127.85M | -$100.70M | -$89.12M | -1.3% |
| Depreciation & amortisation | $1.22M | $1.11M | $1.03M | $966.00K | +10.2% |
| Stock-based compensation | $25.04M | $20.21M | $15.23M | $14.46M | +23.9% |
| Change in working capital | -$5.46M | $1.97M | $4.90M | -$445.00K | -377.4% |
| Operating cash flow | -$110.97M | -$112.66M | -$85.69M | -$75.14M | +1.5% |
| Capital expenditure | -$712.00K | -$1.19M | -$849.00K | -$2.08M | +40.1% |
| Investing cash flow | -$148.03M | $22.14M | -$43.40M | -$109.25M | -768.7% |
| Financing cash flow | $245.26M | $126.55M | $85.66M | $25.23M | +93.8% |
| Free cash flow | -$111.68M | -$113.85M | -$86.54M | -$77.22M | +1.9% |
| End cash position | $46.16M | $59.90M | $23.88M | $67.31M | -22.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $36.30M | $31.44M | $25.86M | $28.77M | $30.55M | +15.5% |
| Selling, general & admin | $9.00M | $8.18M | $8.70M | $7.90M | $8.52M | +10.0% |
| Total operating expense | $45.30M | $39.62M | $34.55M | $36.67M | $39.06M | +14.3% |
| Operating income | -$45.30M | -$39.62M | -$34.55M | -$36.67M | -$39.06M | -14.3% |
| Pre-tax income | -$41.49M | -$35.77M | -$30.50M | -$32.59M | -$36.35M | -16.0% |
| Net income | -$41.49M | -$35.77M | -$30.50M | -$32.59M | -$36.35M | -16.0% |
| Net income to common | -$41.49M | -$35.77M | -$30.50M | -$32.59M | -$36.35M | -16.0% |
| Basic EPS | -0.38 | -0.34 | -0.30 | -0.33 | -0.47 | -11.8% |
| Diluted EPS | -0.38 | -0.34 | -0.30 | -0.33 | -0.47 | -11.8% |
| EBIT | -$45.30M | -$39.62M | -$34.55M | -$36.67M | -$39.06M | -14.3% |
| EBITDA | -$45.03M | -$39.35M | -$34.23M | -$36.38M | -$38.75M | -14.4% |
| Basic shares | 108.01M | 105.47M | 102.59M | 98.95M | 78.13M | +2.4% |
| Diluted shares | 108.01M | 105.47M | 102.59M | 98.95M | 78.13M | +2.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $37.48M | $56.40M | $45.67M | $49.67M | $75.86M | -33.5% |
| Cash & short-term investments | $264.76M | $281.93M | $281.49M | $287.14M | $282.51M | -6.1% |
| Total current assets | $273.69M | $290.23M | $288.47M | $295.59M | $291.12M | -5.7% |
| Property, plant & equipment | $2.24M | $2.15M | $2.42M | $2.56M | $2.76M | +4.4% |
| Total assets | $404.69M | $436.76M | $408.89M | $431.19M | $346.86M | -7.3% |
| Total current liabilities | $20.76M | $17.77M | $20.42M | $20.18M | $18.05M | +16.8% |
| Total debt | $3.33M | $3.30M | $3.33M | $3.30M | $3.27M | +0.9% |
| Total liabilities | $23.43M | $21.20M | $24.53M | $24.27M | $22.86M | +10.5% |
| Retained earnings | -$769.50M | -$728.01M | -$692.24M | -$661.74M | -$629.15M | -5.7% |
| Shareholder equity | $381.26M | $415.56M | $384.36M | $406.92M | $324.00M | -8.3% |
| Working capital | $252.94M | $272.46M | $268.05M | $275.42M | $273.07M | -7.2% |
| Net tangible assets | $381.26M | $415.56M | $384.36M | $406.92M | $324.00M | -8.3% |
| Shares issued | 103.64M | 103.49M | 98.53M | 97.28M | 86.19M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$41.49M | -$35.77M | -$30.50M | -$32.59M | -$36.35M | -16.0% |
| Depreciation & amortisation | $264.00K | $270.00K | $320.00K | $288.00K | $310.00K | -2.2% |
| Stock-based compensation | $7.09M | $6.90M | $6.28M | $5.63M | $6.57M | +2.8% |
| Change in working capital | $2.24M | -$4.00M | $1.66M | $2.14M | -$780.00K | +156.0% |
| Operating cash flow | -$31.61M | -$32.44M | -$22.48M | -$25.11M | -$30.84M | +2.6% |
| Capital expenditure | -$356.00K | -$2.00K | -$227.00K | -$35.00K | -$63.00K | -17,700.0% |
| Investing cash flow | $11.86M | -$17.98M | $16.98M | -$110.53M | -$76.93M | +166.0% |
| Financing cash flow | $828.00K | $61.14M | $1.50M | $109.45M | $134.30M | -98.6% |
| Free cash flow | -$31.96M | -$32.44M | -$22.71M | -$25.15M | -$30.91M | +1.5% |
| End cash position | $37.97M | $56.89M | $46.16M | $50.16M | $76.36M | -33.2% |
Options analytics
Put / call volume
11.15
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
9.00
-24.9% from spot
ATM implied vol
0.8%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
13
Contracts, this expiry
Put volume
145
Contracts, this expiry
Heaviest call OI
11.00
0 contracts
Heaviest put OI
9.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.36 | -0.38 | -5.3% |
| Mar 2026 | -0.32 | -0.34 | -6.0% |
| Dec 2025 | -0.37 | -0.30 | +18.5% |
| Sep 2025 | -0.40 | -0.33 | +17.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.38 | 13 | $0 | 0.0% |
| Next quarter | -0.40 | 13 | $0 | 0.0% |
| Current year | -1.49 | 13 | $0 | 0.0% |
| Next year | -1.67 | 13 | $0 | 0.0% |
Analyst targets & ownership
Mean target$21.43
High target$27.00
Low target$14.00
Implied upside77.83%
Analyst count14
ConsensusSTRONG BUY
Strong buy / Buy2 / 13
Hold1
Sell / Strong sell0 / 0
Held by insiders1.59%
Held by institutions123.12%
Institutions holding245
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
12.90
-6.57% from price
SMA 20
12.75
-6.03% from price
SMA 50
12.97
-7.62% from price
SMA 100
11.18
+7.80% from price
SMA 200
10.87
+10.18% from price
EMA 12
12.71
-5.23% from price
EMA 26
12.80
-5.90% from price
EMA 50
12.54
-3.92% from price
RSI (14)
40.0
Neutral
MACD (12,26,9)
-0.09
Hist -0.11
ATR (14)
0.79
6.57% of price
Realised vol 30D
43.1%
Annualised
Bollinger upper
13.72
20, 2σ
Bollinger lower
11.78
20, 2σ
50 / 200 cross
Golden
12.97 vs 10.87
Trend bias
Above 200
+10.18%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.34
More volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
43.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-48.1%
Peak to trough
Max drawdown 5Y
-86.2%
Peak to trough
ATR 14
0.79
6.57% of price
Beta (reported)
0.98
5Y monthly, from filing
Short interest
Shares short
17.53M
Prior 18.39M
Change vs prior
-4.7%
Shorts covering
% of float
17.09%
Elevated
% of shares out
16.91%
Against total outstanding
Days to cover
15.0
Crowded exit
Float
88.69M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | Leerink Partners | INITIATED | — | Outperform |
| Sep 23, 26 | BTIG | INITIATED | — | Buy |
| Aug 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 8, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 15, 26 | Goldman Sachs | UPGRADE | — | Buy |
| May 5, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Apr 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 1, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Mar 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 24, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Feb 24, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 24, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-03
Corporate Changes & Voting Matters
8-K · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-06-22
Corporate Changes & Voting Matters
8-K · 2026-05-04
Proxy Statements
DEF 14A · 2026-04-28
Corporate Changes & Voting Matters
8-K · 2026-03-31
Corporate Changes & Voting Matters
8-K · 2026-02-23
Corporate Changes & Voting Matters
8-K · 2025-12-08
Headlines
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
GlobeNewswire · 1d ago
Leerink Partners Initiates ORIC Pharmaceuticals at Outperform With $26 Price Target
MT Newswires · 2d ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 4d ago
BTIG Initiates ORIC Pharmaceuticals at Buy With $26 Price Target
MT Newswires · 14d ago
ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch
Insider Monkey · 22d ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 32d ago
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire · 34d ago
Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing
MT Newswires · 39d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.